Tango Therapeutics Inc
NASDAQ:TNGX

Watchlist Manager
Tango Therapeutics Inc Logo
Tango Therapeutics Inc
NASDAQ:TNGX
Watchlist
Price: 6.04 USD -4.13% Market Closed
Market Cap: 654.7m USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one TNGX stock under the Base Case scenario is 2.75 USD. Compared to the current market price of 6.04 USD, Tango Therapeutics Inc is Overvalued by 55%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

TNGX Relative Value
Base Case
2.75 USD
Overvaluation 55%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

15.9
P/S
P/S
Price to Sales
15.9
vs History
43
vs Industry
64
Median 3Y
17.7
Median 5Y
14.7
Industry
7.5
Forward
22.5
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-4.7
Median 5Y
-7.6
Industry
24.4
Forward
-4.4
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-4.7
Median 5Y
-7
Industry
20.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-4.6
Median 5Y
-6.6
Industry
23
More Details
3.9
P/B
P/B
Price to Book Value
3.9
vs History
9
vs Industry
61
Median 3Y
2.5
Median 5Y
1.8
Industry
2.8
More Details
10.6
EV/S
EV/S
Enterprise Value to Sales
10.6
vs History
33
vs Industry
30
Median 3Y
9.3
Median 5Y
5.4
Industry
8
Forward
15
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.2
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
23
Median 3Y
-2.3
Median 5Y
-3.5
Industry
5
Forward
-2.5
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
21
Median 3Y
-2.3
Median 5Y
-3.5
Industry
5
Forward
-2.5
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
25
Median 3Y
-2.3
Median 5Y
-3.6
Industry
5.5
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
21
Median 3Y
-2.2
Median 5Y
-3.6
Industry
3.9
More Details
8.1
EV/IC
EV/IC
Enterprise Value to IC
8.1
vs History
28
vs Industry
20
Median 3Y
4.3
Median 5Y
3
Industry
5
More Details

Multiples Across Competitors

TNGX Competitors Multiples
Tango Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Tango Therapeutics Inc
NASDAQ:TNGX
652.3m USD 15.9 -4.9 -3 -3
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 730 445.2 -165 068.7 -200 446 -198 158.7
US
Abbvie Inc
NYSE:ABBV
344.8B USD 6 83 15.7 23.2
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD 374 305.7 -13 141.6 -13 213.5 -13 207.5
US
Amgen Inc
NASDAQ:AMGN
159.6B USD 4.7 26.9 14.4 23.8
US
Gilead Sciences Inc
NASDAQ:GILD
140.9B USD 4.9 23.6 10.3 14.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.9B USD 10.7 -120.1 25.6 26.8
US
Epizyme Inc
F:EPE
94.1B EUR 2 028.5 -517.6 -563.6 -548.6
AU
CSL Ltd
ASX:CSL
127.9B AUD 5.4 29.9 18.3 23
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.5B USD 4.3 13.4 12 13.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
51.9B USD 22.1 -192.6 -870.6 -436.3
P/S Multiple
Revenue Growth P/S to Growth
US
Tango Therapeutics Inc
NASDAQ:TNGX
Average P/S: 3 191 532.1
15.9
-14%
N/A
FR
Pharnext SCA
OTC:PNEXF
34 730 445.2
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6
8%
0.8
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
374 305.7
140%
2 673.6
US
Amgen Inc
NASDAQ:AMGN
4.7
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.9
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.7
10%
1.1
US
E
Epizyme Inc
F:EPE
2 028.5
N/A N/A
AU
CSL Ltd
ASX:CSL
5.4
7%
0.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.3
4%
1.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
22.1
30%
0.7
P/E Multiple
Earnings Growth PEG
US
Tango Therapeutics Inc
NASDAQ:TNGX
Average P/E: 35.4
Negative Multiple: -4.9 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -165 068.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
83
88%
0.9
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
Negative Multiple: -13 141.6 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
26.9
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23.6
189%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -120.1 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -517.6 N/A N/A
AU
CSL Ltd
ASX:CSL
29.9
16%
1.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.4
7%
1.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -192.6 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Tango Therapeutics Inc
NASDAQ:TNGX
Average EV/EBITDA: 16.1
Negative Multiple: -3 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -200 446 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.7
13%
1.2
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
Negative Multiple: -13 213.5 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
14.4
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10.3
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.6
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.6 N/A N/A
AU
CSL Ltd
ASX:CSL
18.3
11%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12
11%
1.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -870.6 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Tango Therapeutics Inc
NASDAQ:TNGX
Average EV/EBIT: 20.7
Negative Multiple: -3 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -198 158.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.2
29%
0.8
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
Negative Multiple: -13 207.5 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
23.8
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
14.1
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.8
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -548.6 N/A N/A
AU
CSL Ltd
ASX:CSL
23
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.5
11%
1.2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -436.3 N/A N/A

See Also

Summary
TNGX intrinsic value, competitors valuation, and company profile.
DCF Valuation
TNGX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
TNGX stock valuation using valuation multiples.
Wall Street Estimates
TNGX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
TNGX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 271,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.